During the past decade, MacGregor Medical Center conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "MacGregor Medical Center" #1 collaborator was "CoLucid Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "MacGregor Medical Center" are "Diabetes Mellitus, Type 2" (1 trials) and "Migraine Disorders" (1 trials). Many other conditions were trialed in "MacGregor Medical Center" in a lesser frequency.

Most popular intervention types in "MacGregor Medical Center" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Empagliflozin (oral)" (1 trials), "Glimepiride (oral)" (1 trials), "ITCA 650 20/60 mcg/day" (1 trials) and "Lasmiditan" (1 trials). Other intervention names were less common.

The vast majority of trials in "MacGregor Medical Center" are 2 trials for "All" genders.

Currently, there are NaN active trials in "MacGregor Medical Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in MacGregor Medical Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in MacGregor Medical Center, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".